Compare OMDA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMDA | ESPR |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 897.6M | 793.7M |
| IPO Year | 2025 | 2013 |
| Metric | OMDA | ESPR |
|---|---|---|
| Price | $11.32 | $3.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $24.80 | $6.67 |
| AVG Volume (30 Days) | 1.3M | ★ 4.4M |
| Earning Date | 03-05-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $232,342,000.00 | ★ $303,802,000.00 |
| Revenue This Year | $52.49 | $27.49 |
| Revenue Next Year | $22.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 89.23 | 2.83 |
| 52 Week Low | $10.28 | $0.69 |
| 52 Week High | $28.40 | $4.18 |
| Indicator | OMDA | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 25.95 | 49.78 |
| Support Level | $10.28 | $3.16 |
| Resistance Level | $12.05 | $3.52 |
| Average True Range (ATR) | 1.05 | 0.19 |
| MACD | -0.31 | 0.02 |
| Stochastic Oscillator | 14.38 | 53.12 |
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.